Singapore, 14 December 2018 – Janesis Bioscience is pleased to announce that Oncimmune Early CDT-Lung Test Kit is now approved by the Singapore Health Sciences Authority for in-vitro diagnostics (Device Registration No: DE0502280). The test kit has also attained CE-IVD 98/79/EC status in May 2017.
Lung cancer is the uncontrolled growth of abnormal cells in the lungs. This usually occurs in those cells that line the air passages. As the cancer cells grow, they can interfere with the normal functioning of the lungs.
According to the Singapore Cancer Registry, Lung cancer is the second and third most common cancer in males and females respectively. It is a leading cause of more than 6,000 cancer death (27.1% in males and 16.6% in females) between 2011 and 2015. However, when detected early (Stage 1), cure is possible and the survival rates can be as high as 6 out of 10 patients.
The Oncimmune Early CDT-Lung Test is a simple blood test which can be used for early detection of lung cancer or to aid risk assessment of pulmonary nodules. The test detects a panel of 7 autoantibodies produces in reaction to tumour antigens which can arise in the early stages of cancer. Studies have shown that the test is able to detect cancer up to four years in advance, even before symptoms present.
About Janesis Bioscience Pte Ltd
Janesis Bioscience provides emerging and novel solutions to the healthcare ecosystem. With a customer-centric focus, we aim to bring innovative products to improve clinical outcomes and patient lives. We are the sole distributor for Oncimmune in Singapore.
About Oncimmune Ltd
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer.
For more information please contact us at firstname.lastname@example.org.